PSMA-specific uptake of the IRDye800CW (13.6 ± 3.7 %ID/g) and DyLight800 (15.6 ± 5.5 %ID/g) conjugated ligands in the tumor was significantly higher than that of the unconjugated 68Ga-PSMA-11 agent (4.8 ± 1.3 %ID/g). Here, FOLH1 is linked to neoplasm.